for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Esperion Therapeutics Inc

ESPR.OQ

Latest Trade

44.65USD

Change

-1.00(-2.19%)

Volume

83,802

Today's Range

43.43

 - 

45.90

52 Week Range

33.13

 - 

58.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
45.65
Open
45.57
Volume
83,802
3M AVG Volume
8.54
Today's High
45.90
Today's Low
43.43
52 Week High
58.50
52 Week Low
33.13
Shares Out (MIL)
27.33
Market Cap (MIL)
1,247.50
Forward P/E
-12.38
Dividend (Yield %)
--

Next Event

Esperion Therapeutics Inc at Jefferies London Healthcare Conference

Latest Developments

More

Esperion Provides Reports Third Quarter Financial Results

Esperion Completes Patient Enrollment In The Global Clear Cardiovascular Outcomes Trial For Bempedoic Acid

Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid / Ezetimibe Combination Tablet

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

Industry

Biotechnology & Drugs

Contact Info

3891 Ranchero Dr Ste 150

+1.734.8873903

http://www.esperion.com/

Executive Leadership

Timothy M. Mayleben

President, Chief Executive Officer, Director

Richard B. Bartram

Chief Financial Officer

Narendra D. Lalwani

Executive Vice President - Research & Development

Mark A. Glickman

Chief Commercial Officer

Nicole Vitullo

Lead Independent Director

Key Stats

1.83 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-3.330

2017

-6.980

2018

-7.540

2019(E)

-3.628
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.46
Price To Book (MRQ)
18.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-57.82
Return on Equity (TTM)
-44.38

Latest News

Latest News

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

Esperion's cholesterol drug safe, effective in new late-stage study

Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.

BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID

BRIEF-Esperion Posts Qtrly Loss Per Share $1.73

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Esperion's drug clears study as add-on cholesterol treatment

Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients, who were already on another treatment to lower the risk of artery-clogging heart disease.

Esperion's cholesterol drug succeeds in mid-stage study

Esperion Therapeutics Inc said on Tuesday a mid-stage study of its experimental oral drug met the main goal of reducing cholesterol.

BRIEF-Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA

Esperion's cholesterol drug succeeds in late-stage study

Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

BRIEF-Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID

Esperion's cholesterol drug succeeds in late-stage study

Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

BRIEF-Esperion Reports Qtrly Loss Per Share $1.44

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Esperion Announces The Appointment Of Jeffrey Berkowitz To Board Of Directors

* ESPERION ANNOUNCES THE APPOINTMENT OF JEFFREY BERKOWITZ TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Esperion Therapeutics Q3 loss per share $1.86

* Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results

BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid

* Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill

BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018

* Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018

BRIEF-Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc

* Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing Source text (http://bit.ly/2x6jGbc) Further company coverage:

BRIEF-Esperion announces proposed public offering of common stock

* Esperion announces proposed public offering of common stock

BRIEF-Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

* Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin

BRIEF-Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

* Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

BRIEF-Esperion reports Q1 net loss per common share $1.80

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up